| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Giancarlo Maria Liumbruno | Q102063752 |
| P2093 | author name string | Francesco Bennardello | |
| Pierluigi Piccoli | |||
| Gina Rossetti | |||
| Angela Lattanzio | |||
| Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group | |||
| P2860 | cites work | Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation | Q24245960 |
| Neonatal thrombocytopenia: causes and management | Q24673677 | ||
| Transfusion-related acute lung injury: definition and review | Q28244169 | ||
| Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? | Q31040247 | ||
| Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? | Q33240024 | ||
| Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura | Q33328894 | ||
| Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? | Q33333811 | ||
| Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 | ||
| Lowering the prophylactic platelet transfusion threshold: a prospective analysis | Q33337229 | ||
| Platelet transfusion trigger in difficult patients | Q33338491 | ||
| Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. | Q33338940 | ||
| Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions | Q33340587 | ||
| What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? | Q33342383 | ||
| The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy | Q33343369 | ||
| Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes | Q33344705 | ||
| Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias | Q33346559 | ||
| Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy | Q33346561 | ||
| Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura | Q33348253 | ||
| Guidelines for the use of platelet transfusions | Q33348675 | ||
| The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia | Q71008690 | ||
| Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy | Q71137317 | ||
| Contribution of the haematocrit to the bleeding time | Q71185040 | ||
| Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. BCSH Blood Transfusion Task Force | Q71713217 | ||
| Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution | Q71810573 | ||
| Paired in vivo and in vitro comparison of apheresis and "recovered" platelet concentrates stored for 5 days | Q72131986 | ||
| Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists | Q72257155 | ||
| Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients | Q72287822 | ||
| Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL | Q73132195 | ||
| Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity | Q73205703 | ||
| A comparative analysis of different methods for routine blood component preparation | Q73317259 | ||
| Viral safety of solvent/detergent-treated plasma | Q73378230 | ||
| Comparison of Solvent/Detergent-Inactivated Plasma and Fresh Frozen Plasma under Routine Clinical Conditions | Q73949068 | ||
| Italian guidelines for the appropriate use of plasma | Q74007113 | ||
| Efficacy of SD-treated plasma during liver transplantation | Q74105725 | ||
| Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force | Q74503605 | ||
| Transfusion guidelines for neonates and older children | Q76382875 | ||
| Platelet transfusion practice: time for renewed consensus | Q77113099 | ||
| Final statement from the consensus conference on platelet transfusion | Q77113146 | ||
| A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia | Q77363637 | ||
| In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma | Q77467530 | ||
| Guideline for the use of fresh-frozen plasma. Medical Directors Advisory Committee, National Blood Transfusion Council | Q77527630 | ||
| Diagnosis and treatment of patients refractory to platelet transfusions | Q78018274 | ||
| Indications for therapeutic platelet transfusions | Q78018281 | ||
| Practical guidelines for the clinical use of plasma | Q78370916 | ||
| Further enhancement of the safety of human plasma derivatives | Q78388873 | ||
| Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration | Q78388882 | ||
| A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger | Q78523412 | ||
| Coagulant stability and sterility of thawed S/D-treated plasma | Q78631653 | ||
| [Transfusion of fresh coagulated plasma: products, indications. General methods and recommendations] | Q78852240 | ||
| The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness | Q78876195 | ||
| Transfusion-related acute lung injury | Q79192198 | ||
| Guidelines on the management of massive blood loss | Q79361874 | ||
| Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? | Q80031333 | ||
| Apheresis platelet transfusions: does ABO matter? | Q80119513 | ||
| Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas) | Q81017996 | ||
| Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4 degrees C for 6 days | Q81070881 | ||
| [Guide for transfusion of blood components] | Q81264699 | ||
| Transfusion-related acute lung injury | Q81335406 | ||
| [Indications for use of labile blood products and the physiology of blood transfusion in medicine. The French Agency for the Health Safety of Health Products] | Q81748326 | ||
| The NHLBI Clinical Trials Network in transfusion medicine and hemostasis: an overview | Q83163505 | ||
| Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura | Q33360121 | ||
| Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. | Q33360800 | ||
| Optimizing platelet transfusion therapy | Q33361167 | ||
| Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials | Q33361279 | ||
| Solvent/detergent-treated plasma: composition, efficacy, and safety | Q33364635 | ||
| Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients | Q33364823 | ||
| Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? | Q33369562 | ||
| A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation | Q33369834 | ||
| The influence of the haematocrit on primary haemostasis in vitro | Q33369919 | ||
| The management of heparin-induced thrombocytopenia. | Q33371013 | ||
| Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia | Q33371869 | ||
| The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia | Q33372993 | ||
| Factors influencing 20-hour increments after platelet transfusion | Q33389655 | ||
| Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. | Q33451678 | ||
| Clinical impact of neonatal thrombocytopenia | Q33457027 | ||
| Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations | Q33486684 | ||
| Platelet transfusion therapy in newborn infants | Q33488344 | ||
| A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants | Q33493763 | ||
| Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura | Q33496995 | ||
| The volume of blood shed during the bleeding time correlates with the peripheral venous hematocrit | Q33500692 | ||
| The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. | Q33501152 | ||
| Transfusing platelets 2 h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival | Q33502321 | ||
| Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia | Q33502337 | ||
| Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. | Q33504739 | ||
| Prevention and management of platelet transfusion refractoriness | Q33505118 | ||
| Solvent-detergent-treated fresh frozen plasma: a superior alternative to standard fresh frozen plasma? | Q34119102 | ||
| Evidence-based recommendations for the use of WBC-reduced cellular blood components | Q34405086 | ||
| Revisitation of the clinical indications for the transfusion of platelet concentrates | Q34434805 | ||
| Guidelines on oral anticoagulation (warfarin): third edition--2005 update | Q34484090 | ||
| Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy | Q34962428 | ||
| Virus safety of human blood, plasma, and derived products | Q34962485 | ||
| Guidelines for assessing appropriateness of pediatric transfusion. | Q34991606 | ||
| The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility | Q35043259 | ||
| Pathogen inactivated transfusion plasma: existing and emerging methods. | Q35078144 | ||
| Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? | Q35200159 | ||
| Neonatal transfusion practice | Q35556499 | ||
| Current understanding of disseminated intravascular coagulation | Q35661014 | ||
| Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. | Q35688850 | ||
| Correcting haemostasis | Q35807422 | ||
| Transfusion-related acute lung injury: a review | Q35833981 | ||
| Use of blood products in sepsis: an evidence-based review | Q35948806 | ||
| Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review | Q36244563 | ||
| Appraisal of the evidence for the clinical use of FFP and plasma fractions | Q36353429 | ||
| Pathogen inactivation: the definitive safeguard for the blood supply | Q36815115 | ||
| Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology | Q37084857 | ||
| Bleeding time. A guide to its diagnostic and clinical utility | Q38263910 | ||
| Nanofiltration of single plasma donations: feasibility study | Q40603194 | ||
| A practical guide for the diagnosis and treatment of acute sinusitis. | Q41624071 | ||
| Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery | Q42670512 | ||
| Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss | Q43700338 | ||
| Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding | Q43885621 | ||
| The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation | Q44117312 | ||
| Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors | Q44189779 | ||
| Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). | Q45732764 | ||
| Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy | Q45857976 | ||
| Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders | Q45858187 | ||
| Platelet immunopathology and therapy: a Canadian Blood Services Research and Development Symposium | Q45862842 | ||
| Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy | Q47444455 | ||
| Platelet transfusions in the neonatal intensive care unit:factors predicting which patients will require multiple transfusions | Q47622222 | ||
| Proceedings of a consensus conference: towards an understanding of TRALI. | Q47814565 | ||
| Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. | Q50502006 | ||
| Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. | Q50723641 | ||
| Transfusion-related acute lung injury (TRALI)--under-diagnosed and under-reported. | Q51677336 | ||
| Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. | Q53254548 | ||
| Urgent reversal of warfarin with prothrombin complex concentrate. | Q53255644 | ||
| A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. | Q53340662 | ||
| Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrat | Q53539960 | ||
| Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. | Q53656605 | ||
| Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant | Q56675460 | ||
| URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS | Q57705082 | ||
| Acquired protein s deficiency in thrombotic thrombocytopenic purpura patients receiving solvent/detergent plasma exchange | Q60034604 | ||
| Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies | Q61850253 | ||
| Leucocyte-derived bioactive substances in fresh frozen plasma | Q63753667 | ||
| In vitro and in vivo comparison of single-donor platelets and multiple-donor pooled platelets transfusions in leukemic patients | Q67270050 | ||
| Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force | Q67485080 | ||
| The value of 10-minute posttransfusion platelet counts | Q68263337 | ||
| Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions | Q69938467 | ||
| Consensus conference. Fresh-frozen plasma. Indications and risks | Q70052369 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 132-150 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Blood transfusion = Trasfusione del sangue | Q26842792 |
| P1476 | title | Recommendations for the transfusion of plasma and platelets | |
| P478 | volume | 7 |
| Q44691700 | "Low platelet usage" haematology laboratories: To store or not to store? |
| Q55347269 | Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. |
| Q38069965 | Approach to a child with bleeding in the emergency room. |
| Q39179984 | Bio-inspired nanomedicine strategies for artificial blood components |
| Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
| Q35434345 | Blood cell counting in neonates: a comparison between a low volume micromethod and the standard laboratory method |
| Q35919670 | Coagulation defects associated with massive blood transfusion: A large multicenter study |
| Q33416191 | Cochlear implantation is safe and effective in patients with MYH9-related disease |
| Q57689300 | Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders |
| Q37265484 | Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. |
| Q26741073 | Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use |
| Q26748343 | How we treat bleeding associated with direct oral anticoagulants |
| Q91936201 | Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice |
| Q93113230 | Immune Thrombocytopenia is Still the Commonest Diagnosis on Consultative Hematology |
| Q35959374 | Investigation of the current situation of massive blood transfusion in different surgical departments: a large multicenter study in China |
| Q38646788 | Investigation of the status quo of massive blood transfusion in China and a synopsis of the proposed guidelines for massive blood transfusion |
| Q26748355 | Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document |
| Q37417311 | Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. |
| Q28079988 | Making the Switch: Alternatives to Fetal Bovine Serum for Adipose-Derived Stromal Cell Expansion |
| Q21092902 | Management of bleeding and coagulopathy following major trauma: an updated European guideline |
| Q33420773 | Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collections |
| Q38298666 | Perioperative neonatal and paediatric blood transfusion |
| Q35049140 | Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer |
| Q34037018 | Plasma in the PICU: why and when should we transfuse? |
| Q47241256 | Platelet Transfusion Thresholds Among Children Admitted to a Pediatric Intensive Care Unit |
| Q90217546 | Platelet Transfusion: And Update on Challenges and Outcomes |
| Q41958824 | Point of care perioperative coagulation management in liver transplantation and complete portal vein thrombosis. |
| Q47229511 | Prophylactic plasma transfusion for patients undergoing non-cardiac surgery. |
| Q64288183 | Prothrombin Complex Concentrates for Coagulopathy in Liver Disease: Single-Center, Clinical Experience in 105 Patients |
| Q37539104 | Quality Assessment of Established and Emerging Blood Components for Transfusion |
| Q36515685 | Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. |
| Q35049179 | Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn |
| Q34492729 | Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period |
| Q34988663 | Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period |
| Q35106170 | Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period |
| Q35182094 | Reducing noninfectious risks of blood transfusion |
| Q37562996 | Severe sepsis and septic shock: management and performance improvement. |
| Q38433744 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. |
| Q29615429 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 |
| Q27339343 | The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition |
| Q38213013 | The challenge in management of hemorrhagic shock in trauma |
| Q52622931 | The role of thromboelastography in predicting hemorrhage risk in patients with leukemia. |
| Q64260727 | Therapeutic Plasma Exchange in Renal Disorders |
| Q35659166 | Tracheostomy in intensive care unit patients can be performed without bleeding complications in case of normal thromboelastometry results (EXTEM CT) despite increased PT-INR: a prospective pilot study |
| Q42572431 | Transfusion therapy in the peri-operative period |
| Q47578958 | Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization |
Search more.